medigraphic.com
Colegio de Medicina Interna de México.

2024, Number 04

<< Back Next >>

Med Int Mex 2024; 40 (04)

Eosinophilic fasciitis

Pimentel LRR, García CM, Chávez SIN

Language: Spanish
References: 17
Page: 276-282
PDF size: 398.88 Kb.


ABSTRACT

Background: Eosinophilic fasciitis is a rare sclerodermiform syndrome of unknown etiology, characterized by thickening of the muscle fascia and subcutaneous tissue and clinically presents with arthralgia, functional limitation, and thickening of deep tissues that conditions flexion contractures, with variable infiltration by eosinophils and peripheral eosinophilia; the diagnosis requires an adequate approach and, if possible, a skin, muscle and fascia block biopsy. Treatment is discussed and steroids and immunosuppressants are prescribed. Rituximab has currently shown good results in some cases and series.
Clinical case: A 19-year-old female patient who began acutely with skin hardening that lead to functional limitation associated with peripheral eosinophilia; eosinophilic fasciitis was concluded and she had a lack of response to usual treatment, which is why management with rituximab was started, with a good response.
Conclusions: The diagnosis of eosinophilic fasciitis is complex, it requires a high index of suspicion and extensive studies such as magnetic resonance imaging or biopsy; the latter is important but should not delay treatment, which is currently based on steroids and immunosuppressants, with good response; Rituximab may be a therapeutic option in refractory cases.


REFERENCES

  1. Baranski E, Rocha T. Eosinophilic fascitis. An Bras Dermatol 2016; 91 (5 supl 1): S57-9. doi: 10.1590/abd1806-4841.20164683

  2. Ihn H. Eosinophilic fasciitis: From pathophysiology totreatment. Allergol Int 2019; 68: 437-39. doi: 10.1016/j.alit.2019.03.001

  3. Lebeaux D, Sene D. Eosinophilic fasciitis (Shulman disease).Best Pract Res Clin Rheumatol 2012; 26: 449-58. doi:10.1016/j.berh.2012.08.001

  4. Kougkas N, Bertsias G, Papalopoulos I, Repa A, SidiropoulosP, Avgoustidis N. Rituximab for refractory eosinophilicfasciitis: a case series with long-term follow- up andliterature review. Rheumatol Int 2021; 41: 1833-37. doi:10.1007/s00296-021-04887-3

  5. Londono A, Ruiz A, Mesa M. Eosinophilic fasciitis: A casereport. Rev Colomb Reumatol 2018; 25 (1): 63-68.

  6. Minami S, Fujimoto N, Takahashi T, et al. A case of refractoryeosinophilic fasciitis with eosinophilic vasculitis. Eur JDermatol 2016; 26: 319-320. https://doi-org.pbidi.unam.mx:2443/10.1684/ejd.2016.2760

  7. Grados D, Martínez-Morillo M, Tejera B, et al. A commenton “From diagnosis to remission: place of MRI in eosinophilicfasciitis”. Clin Rheumatol 2011; 30: 441-442 https://doi-org.pbidi.unam.mx:2443/10.1007/s10067-010-1670-5

  8. Camard M, Maisonobe T, Flamarion E. The groove sign ineosinophilic fasciitis. Clin Rheumatol 2022. https://doi-org.pbidi.unam.mx:2443/10.1007/s10067-022-06311

  9. Papa R, Nozza P, Granata C, et al. Juvenile eosinophilic fasciitis:report of three cases with a review of the literature.Pediatr Rheumatol 2015; 13: P161. https://doi-org.pbidi.unam.mx:2443/10.1186/1546-0096-13-S1-P161

  10. Barlet J, Virone A, Gomez L, et al. 18F-FDG PET/CT and MRI findingsof Shulman syndrome also known as eosinophilic fasciitis.Eur J Nucl Med Mol Imaging 2021; 48: 2049-2050. https://doi-org.pbidi.unam.mx:2443/10.1007/s00259-020-05172-4

  11. Tyndall A, Fistarol S. The differential diagnosis ofsystemic sclerosis. Current Opinion in Rheumatology2013; 25: 692-699. https://doi.org/10.1097/01.bor.0000434599.51526.47

  12. Jinnin M, Yamamoto T, Asano Y, Ishikawa O, et al. Diagnosticcriteria, severity classification and guidelines of eosinophilicfasciitis. J Dermatol 2018; 45: 881-890. https://doi.org/10.1111/1346-8138.14160

  13. Schattner A, Glick Y. Hidden in plain sight: Eosinophilicfasciitis. Am J Med 2022. https://doi.org/10.1016/j.amjmed.2022.06.011

  14. Long H, Zhang G, Wang L, et al. Enfermedades eosinofílicasde la piel: una revisión exhaustiva. Clin Rev AllergImmunol 2016; 50: 189-213. https://doi-org.pbidi.unam.mx:2443/10.1007/s12016-015-8485-8

  15. Helbig G. Advances in the diagnosis and treatment of eosinophilia.Curr Opin Hematol 2014; 21: 3-7. https://doi.org/10.1097/MOH.0000000000000011

  16. Nahhas AF, Alam M, Lim HW. Rituximab as a therapeuticconsideration for refractory eosinophilic fasciitis. Int JDermatol 2018; 57: 614-615. https://doi-org.pbidi.unam.mx:2443/10.1111/ijd.13940

  17. Thomson GTD, Johnston JL, Thomson BRJ. Eosinophilicfasciitis treated with tocilizumab: Demonstration of efficacyafter withdrawal and re-challenge in a patient. J Rheum DisTreat 2015; 1: 021. DOI: 10.23937/2469-5726/1510021




2020     |     www.medigraphic.com